Summit Global Investments
CSTL icon

Summit Global Investments’s Castle Biosciences CSTL Stock Holding History

Summit Global Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$465K Hold
13,078
– – 0.02% 372
2026
Q2 		$312K Sell
13,078
-640
-5% -$14.3K 0.02% 442
2026
Q1 		$337K Buy
13,718
+1,353
+11% +$44.3K 0.02% 397
2025
Q4 		$481K Buy
12,365
+13
+0.1% +$419 0.03% 325
2025
Q3 		$281K Sell
12,352
-3,297
-21% -$67K 0.02% 406
2025
Q2 		$320K Sell
15,649
-14,991
-49% -$278K 0.02% 381
2025
Q1 		$613K Buy
30,640
+2,164
+8% +$53.6K 0.04% 261
2024
Q4 		$759K Sell
28,476
-1,965
-6% -$59.8K 0.05% 272
2024
Q3 		$868K Buy
30,441
+6,629
+28% +$169K 0.06% 259
2024
Q2 		$518K Buy
+23,812
New +$531K 0.03% 339

Other funds holding CSTL

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Summit Global Investments's CSTL Position: Q3 2026 in Review

Summit Global Investments held its Castle Biosciences (CSTL) position steady in Q3 2026 at 13,078 shares worth $465K. The position accounts for 0.02% of the portfolio, ranked #372.

Summit Global Investments first reported a position in CSTL in Q2 2024 and has held it in 10 quarters since. The position peaked at $868K in Q3 2024. 148 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Summit Global Investments held 13,078 shares of Castle Biosciences worth $465K as of Q3 2026.
  • Summit Global Investments left its Castle Biosciences share count unchanged in Q3 2026.
  • Castle Biosciences made up 0.02% of Summit Global Investments's portfolio in Q3 2026, its #372 holding.
  • Summit Global Investments first reported a position in Castle Biosciences in Q2 2024 and has held it in 10 quarters since.
  • Summit Global Investments's Castle Biosciences position peaked at $868K in Q3 2024.
  • 148 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Summit Global Investments's 13F filing for Q3 2026, filed 28 Oct 2026.